---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-257423"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2026-06-04T20:15:16+00:00"
generated_at: "2026-06-04T20:47:17.053351+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve amended 2024 equity plan with 3.23M share increase and modified evergreen provision

## Summary
- Shareholders approved one-time increase of 3,231,638 shares (approx. 8% of outstanding) to the 2024 Equity Incentive Plan.
- Annual evergreen provision amended: fixed cap of 2,407,100 shares removed; future annual increase set at 5% of outstanding shares beginning FY2027.
- Directors R. Michael Carruthers, Valerie M. Jansen, and Edward T. Mathers elected as Class II directors until 2029.
- Shareholders ratified KPMG LLP as independent auditor for fiscal year ending Dec. 31, 2026.
- Incentive stock option limit under plan set at 8 million shares.

## SEC filing metadata
- accession: 0001193125-26-257423
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2026-06-04T20:15:16+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/0001193125-26-257423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/okur-20260603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-257423
- JSON: https://secwatch.observer/filing/0001193125-26-257423.json
- Plain text: https://secwatch.observer/filing/0001193125-26-257423.txt

## Key facts
- Shareholder Votes
  OnKure Therapeutics, Inc. shareholders approved Approval of the Amended and Restated 2024 Equity Incentive Plan at the 2026-06-03 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: For Against Abstentions Broker Non-Votes 16,431,575 3,490,523 1,895 5,466,123
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/0001193125-26-257423-index.htm
- Shareholder Votes
  OnKure Therapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-03 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: R. Michael Carruthers 19,776,757 147,236 5,466,123 Valerie M. Jansen, M.D., Ph.D. 17,796,919 2,127,074 5,466,123 Edward T. Mathers 19,855,396 68,597 5,466,123
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/0001193125-26-257423-index.htm
- Shareholder Votes
  OnKure Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as independent registered public accounting firm at the 2026-06-03 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: For Against Abstentions Broker Non-Votes 25,329,425 60,370 321 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312526257423/0001193125-26-257423-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.